THe effect of canagliflozin on active GLP-1 levels and betatrophin in patients with type 2 diabetes (CANARIA-STUDY)
Not Applicable
- Conditions
- Type 2 diabetes
- Registration Number
- JPRN-UMIN000016539
- Lead Sponsor
- Dokkyo Medical University Koshigaya Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Not provided
Exclusion Criteria
1)Patients with type 1 diabetes, pancreatic diabetes or secondary diabetes (Cushing syndrome, acromegaly etc.) diabetic coma or diabetic pre-coma, or type 1 diabetes 2)Patients who are not candidated for canagliflozin or teneligliptin treatment 3)Patients under insulin treatment 4)Heavy alcohol consumer (more than or equal to 60 g/day of pure alcohol ) 5)Patients under pregnancy, possible pregnancy, or lactation 6)Patients with severe renal dysfunction (Cr >2.4 mg/dL or Ccr <30 mL/min) 7)Furthermore, patients judged as inadequacy for participation in this study by medical doctor
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Fasting plasma glucose, glucose after meal test, active plasma GLP-1 level, active serum betatrophin level
- Secondary Outcome Measures
Name Time Method Plasma GIP level